# Eli Lilly & Company - Inspection Records Source: https://www.globalkeysolutions.net/companies/eli-lilly-company/fc56eed7-d261-4de3-865e-c2aa54162adf > Inspection records and compliance data for Eli Lilly & Company in Indianapolis, Indiana. Access full analysis and detailed observations. --- ## Details - Name: Eli Lilly & Company - FEI Number: 1819470 - City: Indianapolis - State: Indiana - Country Name: United States - Address Line 1: 1 Lilly Corporate Ctr - Zip Code: 46285 - Facility Type: Sterile Human Drug Manufacturer ## Related Documents - [FDA Inspection 1298628 - Eli Lilly & Company - 2026-01-09](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/2dba8d12-4ce7-4911-b7d2-d04cc01b2be0) — source: FDA, date: January 9, 2026 - [FDA Inspection 1298628 - Eli Lilly & Company - 2026-01-09](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/588c5618-399c-4fcd-8a5d-2b3129fb789a) — classification: No Action Indicated (NAI), source: FDA, date: January 9, 2026 - [483 - Eli Lilly & Company - 2025-05-20](https://www.globalkeysolutions.net/records/483/eli-lilly-company/885fecd9-f6cd-48fd-90eb-66d12ec35d07) — source: FDA, date: May 20, 2025 - [FDA Inspection 1270621 - Eli Lilly & Company - 2025-05-20](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/fef8c0ae-2da9-4018-a496-4396a5db1b07) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 20, 2025 - [FDA Inspection 1270621 - Eli Lilly & Company - 2025-05-20](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/809cae3e-94ad-47cf-a116-8f4799dc570f) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 20, 2025 - [FDA Inspection 1260339 - Eli Lilly & Company - 2025-03-27](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/fcdf8499-2933-4ba0-907d-711ccf9ded98) — source: FDA, date: March 27, 2025 - [FDA Inspection 1260339 - Eli Lilly & Company - 2025-03-27](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/163c6fcd-36a1-439f-a2f3-2ae7265a9f7b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 27, 2025 - [FDA Inspection 1229895 - Eli Lilly & Company - 2025-01-15](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/5a0548a6-c17a-4e25-a426-b05a2c09274b) — source: FDA, date: January 15, 2025 - [FDA Inspection 1229895 - Eli Lilly & Company - 2025-01-15](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/c909e383-5fe7-4ab9-afa8-f4afebe6af9c) — classification: No Action Indicated (NAI), source: FDA, date: January 15, 2025 - [483 - Eli Lilly & Company - 2023-10-06](https://www.globalkeysolutions.net/records/483/eli-lilly-company/f0349542-8a47-4147-9164-7ecacf1fcd4e) — source: FDA, date: October 6, 2023 - [483 - Eli Lilly & Company - 2023-10-06](https://www.globalkeysolutions.net/records/483/eli-lilly-company/d4bd2e3f-d3e2-4c57-a46e-f2bedba3c548) — source: FDA, date: October 6, 2023 - [483 - Eli Lilly & Company - 2023-09-15](https://www.globalkeysolutions.net/records/483/eli-lilly-company/49ac02bf-312b-43ae-96e2-4cf015602e85) — source: FDA, date: September 15, 2023 - [FDA Inspection 1217806 - Eli Lilly & Company - 2023-09-15](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/e798a151-3f7b-4506-b880-321ebcca71a6) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 15, 2023 - [483 - Eli Lilly & Company - 2023-06-16](https://www.globalkeysolutions.net/records/483/eli-lilly-company/ad3d5c22-c165-4f63-91cc-163c31217be2) — source: FDA, date: June 16, 2023 - [483 - Eli Lilly & Company - 2023-06-16](https://www.globalkeysolutions.net/records/483/eli-lilly-company/e0e64c78-d355-4e57-a6a4-bb4f29e29cb5) — source: FDA, date: June 16, 2023 - [EIR - Eli Lilly & Company - 2023-05-18](https://www.globalkeysolutions.net/records/eir/eli-lilly-company/15f9ed35-a475-4557-b1f2-753ea60f17a2) — source: FDA, date: May 18, 2023 - [FDA Inspection 1207271 - Eli Lilly & Company - 2023-05-18](https://www.globalkeysolutions.net/records/fda_inspections/eli-lilly-company/03e44378-5a51-4cdd-93b9-d7017c18aae6) — classification: No Action Indicated (NAI), source: FDA, date: May 18, 2023 - [483 - Eli Lilly & Company - 2022-10-21](https://www.globalkeysolutions.net/records/483/eli-lilly-company/18ee6771-3641-4129-8c43-efe275d11ed4) — source: FDA, date: October 21, 2022 - [483 - Eli Lilly & Company - 2022-10-17](https://www.globalkeysolutions.net/records/483/eli-lilly-company/0122f6aa-1103-4f80-a3f6-6abe81842b50) — source: FDA, date: October 17, 2022 - [483 - Eli Lilly & Company - 2021-03-16](https://www.globalkeysolutions.net/records/483/eli-lilly-company/9fdf10fc-bc85-478c-affd-9279176c5cb7) — source: FDA, date: March 16, 2021 ## Related Companies - [Ferring Microbiome Inc.](https://www.globalkeysolutions.net/companies/ferring-microbiome-inc/860d4130-d93a-4017-97ca-30033280de85) - [Amgen Manufacturing Ltd](https://www.globalkeysolutions.net/companies/amgen-manufacturing-ltd/cecb788c-4cd6-4c26-9331-7b68b4f12369) - [Zoetis LLC](https://www.globalkeysolutions.net/companies/zoetis-llc/1ea95bb9-fb5b-458d-bfff-ca0195c13aa6) - [Baxalta US Inc.](https://www.globalkeysolutions.net/companies/baxalta-us-inc/dd00e45b-9175-4b17-82d5-b189a034a97f) - [FUJIFILM Diosynth Biotechnologies Denmark ApS](https://www.globalkeysolutions.net/companies/fujifilm-diosynth-biotechnologies-denmark-aps/513b3c42-1517-43bc-936a-d3edd26bed70) - [Gland Pharma Limited](https://www.globalkeysolutions.net/companies/gland-pharma-limited/9d02bb1e-32f9-45c5-9b90-f52622553c63) - [ALK-Abello, Inc.](https://www.globalkeysolutions.net/companies/alk-abello-inc/b626f86d-b379-45aa-96d2-0661e9d1c981) - [Novartis Pharma Stein AG](https://www.globalkeysolutions.net/companies/novartis-pharma-stein-ag/06be1f01-8421-471e-9d38-475fef9a9c5b) - [Bristol-Myers Squibb Company](https://www.globalkeysolutions.net/companies/bristol-myers-squibb-company/3734a119-014f-49c6-b518-fc8b1dea7f92) - [Baxalta Belgium Manufacturing SA](https://www.globalkeysolutions.net/companies/baxalta-belgium-manufacturing-sa/61b3acce-a147-4f22-b13a-34bb436ea8e9) ## Related Officers - [Qiao Y. Bobo](https://www.globalkeysolutions.net/people/qiao-y-bobo/c57c1128-9181-4c2a-81f9-cb9a171ece38) - [Senior Regulatory Specialist](https://www.globalkeysolutions.net/people/wayne-e-seifert/e92e1f10-c61e-4b08-9156-25907e5e2942) - [company_representative](https://www.globalkeysolutions.net/people/gottlieb-glauninger/05a6904c-7ff4-4fbd-bb85-8da97d76d8bc) - [recipient](https://www.globalkeysolutions.net/people/fabio-nofrini/07668ef7-9f12-4716-9705-eabdcecc4cc9) - [Eva Dokoupilova](https://www.globalkeysolutions.net/people/eva-dokoupilova/002605cc-8538-4cdb-8f91-9aac427c91b8) - [Senior Policy Advisor](https://www.globalkeysolutions.net/people/cesar-e-matto/016984b7-0a3d-4914-b84d-9e9adcbbeae2)